Literature DB >> 8129618

Cyclosporin A inhibits vaccinia virus replication in vitro.

C R Damaso1, S J Keller.   

Abstract

The effect of the immune modulator, Cyclosporin A (CsA) on vaccinia virus replication has been examined in cell cultures. In the present study we report that CsA is anti-viral towards vaccinia virus. Viral yield was inhibited by more than 97% after 24 h postinfection in the presence of 16 microM to 40 microM CsA. An analysis of the infectious cycle in greater detail revealed that CsA did not effect the total level of [35S] methionine incorporation into vaccinia infected cells. However, both early and late viral gene expression were inhibited by CsA. Late viral protein synthesis appeared to be more sensitive to the drug. At least one late viral polypeptide of approximately Mr 38,000 was virtually undetected up to 8 h postinfection in the presence of 40 microM CsA. Host protein synthesis which is normally inhibited by the virus was not turned off until very late in infection. Viral DNA replication was also inhibited by the addition of CsA at levels comparable to those observed for late protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8129618     DOI: 10.1007/bf01310569

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  36 in total

Review 1.  Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function.

Authors:  J R Bennink; J W Yewdell
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  Protein synthesis in vaccinia virus-infected cells. I. Effect of hypertonic shock recovery.

Authors:  C R Dâmaso; N Moussatché
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

Review 3.  When worlds collide: immunosuppressants meet protein phosphatases.

Authors:  F McKeon
Journal:  Cell       Date:  1991-09-06       Impact factor: 41.582

Review 4.  Poxvirus-based vectors as vaccine candidates.

Authors:  J Tartaglia; S Pincus; E Paoletti
Journal:  Crit Rev Immunol       Date:  1990       Impact factor: 2.214

5.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

6.  Structure of vaccinia virus early promoters.

Authors:  A J Davison; B Moss
Journal:  J Mol Biol       Date:  1989-12-20       Impact factor: 5.469

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 8.  Vaccinia virus: a tool for research and vaccine development.

Authors:  B Moss
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

Review 9.  Cyclosporin A: new insights for cell biologists and biochemists.

Authors:  R J Hohman; T Hultsch
Journal:  New Biol       Date:  1990-08

10.  Cyclophilin: a specific cytosolic binding protein for cyclosporin A.

Authors:  R E Handschumacher; M W Harding; J Rice; R J Drugge; D W Speicher
Journal:  Science       Date:  1984-11-02       Impact factor: 47.728

View more
  12 in total

1.  Human coronavirus-induced neuronal programmed cell death is cyclophilin d dependent and potentially caspase dispensable.

Authors:  Dominique J Favreau; Mathieu Meessen-Pinard; Marc Desforges; Pierre J Talbot
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

2.  Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis.

Authors:  Adriaan H de Wilde; Yanhua Li; Yvonne van der Meer; Grégoire Vuagniaux; Robert Lysek; Ying Fang; Eric J Snijder; Martijn J van Hemert
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

3.  Redistribution of cyclophilin A to viral factories during vaccinia virus infection and its incorporation into mature particles.

Authors:  Ana Paula V Castro; Técia M U Carvalho; Nissin Moussatché; Clarissa R A Damaso
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression.

Authors:  Katherine A Barraclough; Nicole M Isbel; Christine E Staatz; David W Johnson
Journal:  J Transplant       Date:  2011-06-02

5.  Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways.

Authors:  Xiaoling Liu; Zhendong Zhao; Zheng Li; Chongfeng Xu; Lei Sun; Jilong Chen; Wenjun Liu
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

6.  Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506.

Authors:  Javier Carbajo-Lozoya; Marcel A Müller; Stephan Kallies; Volker Thiel; Christian Drosten; Albrecht von Brunn
Journal:  Virus Res       Date:  2012-02-10       Impact factor: 3.303

Review 7.  Virus-host interactomes--antiviral drug discovery.

Authors:  Yue Ma-Lauer; Jian Lei; Rolf Hilgenfeld; Albrecht von Brunn
Journal:  Curr Opin Virol       Date:  2012-10       Impact factor: 7.090

8.  Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro.

Authors:  John M Robida; Heather B Nelson; Zhe Liu; Hengli Tang
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

9.  The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study.

Authors:  Roberto J Firpi; Consuelo Soldevila-Pico; Giuseppe G Morelli; Roniel Cabrera; Cynthia Levy; Virginia C Clark; Amitabh Suman; Anthony Michaels; Chaoru Chen; David R Nelson
Journal:  Dig Dis Sci       Date:  2010-01       Impact factor: 3.487

Review 10.  Curing a viral infection by targeting the host: the example of cyclophilin inhibitors.

Authors:  Kai Lin; Philippe Gallay
Journal:  Antiviral Res       Date:  2013-04-08       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.